Shares of US drug developer Intercept Pharmaceuticals (Nasdaq: ICPT) closed almost 14% lower at $16.12 on Friday, after it revealed that the US regulator will hold an advisory committee (AdCom) meeting to review its re-submitted approval request for its investigational non-alcoholic steatohepatitis (NASH) treatment obeticholic acid (OCA).
The Gastrointestinal Drugs Advisory Committee (GIDAC) of the US Food and Drug Administration (FDA) will discuss Intercept’s new drug application (NDA) for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to NASH on May 19, 2023. The Advisory Committee Meeting will be hosted as a virtual meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze